Health-resource use and quality of life in children with bronchiectasis

A multi-center pilot cohort study

Lovie-Toon, Yolanda G.; Grimwood, Keith; Byrnes, Catherine A.; Goyal, Vikas; Busch, Greta; Masters, I. Brent; Marchant, Julie M.; Buntain, Helen; O'Grady, Kerry Ann F.; Chang, Anne B.

Published in:
BMC Health Services Research

DOI:
10.1186/s12913-019-4414-5

Published: 13/08/2019

Document Version
Publisher's PDF, also known as Version of record

Link to publication

Citation for published version (APA):
Lovie-Toon, Y. G., Grimwood, K., Byrnes, C. A., Goyal, V., Busch, G., Masters, I. B., Marchant, J. M., Buntain, H., O'Grady, K. A. F., & Chang, A. B. (2019). Health-resource use and quality of life in children with bronchiectasis: A multi-center pilot cohort study. BMC Health Services Research, 19, 1-9. [561]. https://doi.org/10.1186/s12913-019-4414-5

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Health-resource use and quality of life in children with bronchiectasis: a multi-center pilot cohort study

Yolanda G. Lovie-Toon, Keith Grimwood, Catherine A. Byrnes, Vikas Goyal, Greta Busch, I. Brent Masters, Julie M. Marchant, Helen Buntain, Kerry-Ann F. O’Grady and Anne B. Chang

Abstract

Background: Bronchiectasis in children is an important, but under-researched, chronic pulmonary disorder that has negative impacts on health-related quality of life. Despite this, it does not receive the same attention as other chronic pulmonary conditions in children such as cystic fibrosis. We measured health resource use and health-related quality of life over a 12-month period in children with bronchiectasis.

Methods: We undertook a prospective cohort study of 85 children aged <18-years with high-resolution chest computed-tomography confirmed bronchiectasis undergoing management in three pediatric respiratory medical clinics in Darwin and Brisbane, Australia and Auckland, New Zealand. Children with cystic fibrosis or receiving cancer treatment were excluded. Data collected included the frequency of healthcare attendances (general practice, specialists, hospital and/or emergency departments, and other), medication use, work and school/childcare absences for parents/carers and children respectively, and both parent/carer and child reported quality of life and cough severity.

Results: Overall, 951 child-months of observation were completed for 85 children (median age 8.7-years, interquartile range 5.4–11.3). The mean (standard deviation) number of exacerbations was 3.3 (2.2) per child-year. Thirty of 264 (11.4%) exacerbation episodes required hospitalization. Healthcare attendance and antibiotic use rates were high (30 and 50 per 100 child-months of observation respectively). A carer took leave from work for 53/236 (22.5%) routine clinic visits. Absences from school/childcare due to bronchiectasis were 24.9 children per 100 child-months. Quality of life scores for both the parent/carer and child were highly-correlated with one another, remained stable over time and were negatively associated with cough severity.

Conclusions: Health resource use in this cohort of children is high, reflecting their severe disease burden. Studies are now needed to quantify the direct and societal costs of disease and to evaluate interventions that may reduce disease burden, particularly hospitalizations.

Keywords: Bronchiectasis, Children, Health-related quality of life, Health resource use
Background
Bronchiectasis is a chronic pulmonary disorder characterized by persistent wet or productive cough, recurrent exacerbations and abnormal dilatation of bronchial airways [1]. The prevalence in children is highest in low-income countries and Indigenous populations [2, 3], and the adverse impact on the child and carer’s quality of life (QoL) is increasingly recognised [4]. Illnesses that consume extensive health resources attract the attention of policy makers and funders [5]. Consequently, the European Multicentre Bronchiectasis Audit and Research Collaboration has recently identified healthcare utilisation as a research priority [6]. However, in children with bronchiectasis few studies describe its impact upon individuals and healthcare services. The limited published data from Australia and New Zealand are derived from hospital cohort studies [7, 8] or clinical trials [9], which cannot be generalized to out-patient or community settings. While in New Zealand the estimated cost of pediatric bronchiectasis hospitalizations was NZD 0.95 million in the 2012/13 financial year [8], there are no similar published Australian data on healthcare service utilization or costs related to bronchiectasis.

Thus, with the aim of informing government healthcare services and future research, our primary objective was to estimate healthcare resource use over a 12-month period for children aged < 18-years with bronchiectasis receiving ongoing care in pediatric respiratory medical centers. Our secondary objective was to measure and correlate the health-related QoL of parents/carers and children with bronchiectasis.

Methods
Study design
Eligible children with bronchiectasis were recruited from respiratory clinics in two Australian (Brisbane and Darwin) and one New Zealand (Auckland) public hospitals between December 2012 and January 2016 and followed for 12-months. Inclusion criteria were aged < 18-years, chest computed-tomography confirmed bronchiectasis and cared for by a respiratory physician. Children with cystic fibrosis, enrolled in another study or receiving treatment for cancer were excluded. Research nurses approached potential participants during routine respiratory clinic appointments to obtain consent to participate.

Data collection
Demographic and bronchiectasis-related characteristics were collected upon enrolment. Research nurses conducted monthly reviews by phone, email or in person, where they recorded types of healthcare sought and school/childcare/work absences due to bronchiectasis, as well as any medications taken and exacerbations in the previous month. An exacerbation was defined as the child being unwell for ≥3-days with at least one of the following symptoms: an increased cough, change in cough quality, or increased sputum volume or purulence [10]. This definition has been used in randomized controlled trials in pediatric bronchiectasis [9, 11]. All exacerbations were reported by parent/carers who had been instructed by research staff on the symptoms constituting the study definition of an exacerbation. When an exacerbation was reported, additional information on resource use for the exacerbation was collected from the parent/carer. All resource utilisation collected through monthly reviews were parent-reported and not confirmed by other sources (e.g. medical records). Face-to-face-clinical visits were scheduled quarterly in accordance with routine clinical practice at the participating hospitals.

Parent/carer-reported and/or child-reported QoL and cough severity were assessed using validated tools at baseline and at months 3, 6, 9 and 12. These data were collected either face-to-face at clinic visits, or through telephone interviews. Parent/carers completed the Parent Cough-specific QoL questionnaire (PC-QoL) [12] and children aged ≥7-years completed the Child Cough-specific QoL questionnaire (CC-QoL) [13]. In both tools, the QoL scores range from 1 (low QoL) to 7 (high QoL). Cough severity was measured using a cough score (0 = no cough to 5 = severe cough and cannot perform usual activities) [14].

Sample size
As this was a pilot study, a specific sample size was not calculated. The target enrolment was 100 children, to achieve a complete dataset on 80 children.

Data analysis
Baseline demographic and bronchiectasis-related characteristics were analyzed descriptively and expressed as counts and proportions, means (standard deviation [SD]) or medians (inter-quartile range [IQR]). Resource use was summarized as the number and proportion of children reporting each type of resource use in the past month, during exacerbations, and at routine clinic visits. Rates of resource use over the 12-months were calculated as the number of children using a particular resource per 100 child-months of observation. Exacerbation-related resource use was summarized for all exacerbations and by season of exacerbation onset. Season of exacerbation onset was categorized as spring (September–November), summer (December–February), autumn (March–May), and winter (June–August) using date of exacerbation onset. Parent/carer and child-reported QoL was summarized by each clinical visit. The Pearson or Spearman correlation coefficients were used
to analyze relationships between parent- and child-reported QoL, parent- and child-reported cough severity, and parent- and child-reported QoL against parent- and child-reported cough severity.

Results

Participant baseline characteristics
The target of 100 enrolled children was reached. The data for 15 were considered too unreliable for meaningful analysis, due to reporting errors or situations where study procedures had not been followed. These participants were subsequently excluded.

The 85 children (42 female, 34 Indigenous Australian/New Zealand subjects) were recruited from the Queensland Children’s Hospital (n = 47), Auckland Starship Children’s Hospital (n = 26) and Royal Darwin Hospital (n = 12). The median age at enrolment was 8.7 (IQR 5.4–11.3) years and their median age at diagnosis of bronchiectasis was 3.6 (IQR 2.1–6.5) years. The median time since diagnosis was 2.9 (IQR 1.7–6.1) years with a mean of 2.6 (SD 1.1) lobes affected. The primary etiology was post-infectious (n = 51), followed by idiopathic (n = 14), aspiration (n = 7) and other (n = 13).

Monthly reviews
Overall, 951 monthly follow-up reviews were completed over the study period. Completions declined over the 12-months (Table 1). There was a greater proportion of children aged < 5 years, with a low birthweight (<2500 g) and who were born pre-term (gestational age <37-weeks) among participants who completed all 12-monthly follow-ups, compared to participants who did not (Additional file 1: Table S3). On average, within the cohort 30 children/100-months of observation attended a general practitioner (GP), emergency department (ED) or pediatric specialist physician for their bronchiectasis, while the corresponding rate for other health reasons was 17 children/100-months. The number of attendances per child per month was not collected. More children presented to a specialist for their management than GPs, and EDs were used infrequently. In any given month, over half of the children were taking some form of medication. Medication use was not specified for bronchiectasis only, and the number of courses used per month was not collected.

In any given month, approximately one-quarter of children within the cohort missed some period of school or childcare due to their bronchiectasis; fewer parents/carer missed work. The median number of days missed per child-month ranged from 2.5 (IQR 1.0–4.0) to 4.0 (IQR 2.0–7.0).

Exacerbations
Overall, 276 bronchiectasis exacerbations were reported (mean 3.3 [SD 2.2] per child-year). Twelve episodes had missing data for resource use associated with the exacerbation, leaving 264 for analysis (Table 2). Of these, 59 (22%) began in spring, 54 (20%) in summer, 62 (23%) in autumn, and 82 (31%) began in winter, while for 7 (3%) onset season was unknown. Overall when looking solely at exacerbations, GPs were the most frequently used healthcare resource. Thirty episodes resulted in hospitalization; 20/264 (7.6%) were treated exclusively in hospital (mean stay 6.7 [SD 4.8] days), while 10/264 (3.8%) had “hospital-in-the-home” following their in-patient stay (mean length of care 9.0 [SD 2.4] days). Parents reported they had antibiotics at home (or a prescription to fill) in approximately one-third of exacerbations. A bronchoscopy was performed on one occasion. The frequency of resource use varied by season, however variations were inconsistent between different types of healthcare resource use. Frequency of use was highest during spring for GPs and specialists, highest during summer for hospitalizations, and highest during winter for antibiotic consumption.

Clinic visits
Most children (77/85) completed a clinic visit at baseline. Approximately half of the cohort completed clinic visits and the corresponding questionnaire at the four subsequent time-points (Table 3). Consultant respiratory physicians were the most common clinicians present at the review (192/236; 81.4%), while respiratory function testing (154/236; 65.3%) and physiotherapy (85/236; 36.0%) were the most frequently used additional clinical services. Parents/carer took leave from work to attend the appointment in 53/236 (22.5%) clinic visits.

Quality of life and cough severity
Similar to clinic visits, QoL and cough severity questionnaire completions were high at baseline, but decreased at subsequent time-points (Table 4). Whether the child was experiencing an exacerbation at the time the QoL and cough severity questionnaires were completed was not recorded. Median parent/carer and child QoL scores were consistent across all time-points (Table 4). Parent/carer scores ranged from 5.9 (IQR 4.3–6.8) to 6.5 (IQR 5.4–6.9) and child scores ranged from 6.1 (IQR 4.5–6.7) to 6.8 (IQR 5.0–7.0). Median parent/carer and child-reported cough severity scores ranged from 1.0 (IQR 0.0–2.0) to 2.0 (IQR 0.0–2.0) and from 1.0 (IQR 0.0–2.0) to 2.0 (IQR 0.5–2.5), respectively (Additional file 1: Table S1).

Whilst small numbers of participants completed both PC-QoL and CC-QoL questionnaires at each time-point (Additional file 1: Table S2), there were high and significant positive correlations between parent/carer and child QoL scores at each time-point (p-values < 0.002). There were also high positive correlations between parent-
reported and child-reported cough severity scores. High negative correlations were observed between child-reported cough severity and QoL scores at each time-point and between parent/carer-reported cough severity and QoL scores.

**Discussion**

Here, we described the annual health resource use and parent/carer and child QoL scores in children with bronchiectasis managed at two Australian and one New Zealand hospitals. In this cohort, children averaged three exacerbations per annum. In any given month, approximately one-third of the cohort presented for medical care, half used antibiotics and one-quarter had absences from school or childcare. Parents/carers sought medical care from a specialist more frequently than GPs or EDs, except during exacerbations. While exacerbations were more frequent in winter, seasonal frequency of exacerbation-related resource use varied between types of resource use. Eleven-percent of exacerbations resulted in hospitalization, and in one-third this included subsequent “hospital-in-the-home” care. Although over time QoL scores for both parents/carers and children were high and stable, better QoL was significantly associated with low cough severity.

There are limited published Australian or New Zealand data on health-related resource use in children or adults with bronchiectasis with which to compare our findings. Redding et al. [15] reported that among Indigenous Australian and Alaskan children aged <8-years, 15% of

---

**Table 1** Monthly medical resource use, missed school and childcare, and missed parent/carer work (N = 85 children)

| Month  | 1          | 2          | 3          | 4          | 5          | 6          | 7          | 8          | 9          | 10         | 11         | 12         | TOTAL Per 100 child-mths |
|--------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|--------------------------|
| 1      | 82         | 84         | 82         | 83         | 80         | 80         | 79         | 78         | 78         | 75         | 72         | 951        | N/A                      |
| Saw GP |            |            |            |            |            |            |            |            |            |            |            |            |                          |
| For bronchiectasis | 7          | 7          | 8          | 11         | 10         | 14         | 11         | 13         | 9          | 12         | 8          | 8          | 118                     |
| For other reason   | 4          | 8          | 6          | 7          | 5          | 3          | 6          | 8          | 6          | 2          | 3          | 7          | 65                      |
| Saw ED |            |            |            |            |            |            |            |            |            |            |            |            |                          |
| For bronchiectasis | 5          | 3          | 2          | 1          | 1          | 0          | 2          | 1          | 2          | 0          | 1          | 0          | 17                      |
| For other reason   | 3          | 0          | 0          | 1          | 0          | 2          | 1          | 0          | 0          | 1          | 1          | 9          | 10                      |
| Saw specialist |            |            |            |            |            |            |            |            |            |            |            |            |                          |
| For bronchiectasis | 11         | 7          | 12         | 14         | 15         | 14         | 9          | 12         | 12         | 14         | 13         | 14         | 147                     |
| For other reason   | 6          | 10         | 9          | 7          | 5          | 10         | 8          | 8          | 7          | 6          | 7          | 6          | 89                     |
| Had medications for any reason | 51         | 47         | 48         | 53         | 51         | 52         | 48         | 52         | 46         | 48         | 43         | 40         | 579                     |
| Had antibiotics for any reason | 37         | 34         | 35         | 40         | 37         | 39         | 36         | 42         | 36         | 37         | 35         | 29         | 437                     |
| Had inhaled corticosteroids for any reason | 9          | 13         | 11         | 15         | 11         | 12         | 12         | 11         | 12         | 9          | 6          | 8          | 129                     |
| Missed school/childcare | 21         | 17         | 15         | 20         | 22         | 26         | 18         | 22         | 19         | 21         | 20         | 16         | 237                    |
| Primary carer missed work | 10         | 9          | 9          | 6          | 5          | 10         | 8          | 10         | 13         | 9          | 11         | 10        | 110                    |
| Secondary carer missed work | 4          | 4          | 5          | 2          | 2          | 4          | 1          | 2          | 3          | 3          | 2          | 1          | 33                     |
| Median days missed school/childcare (IQR) | 3 (2–7)     | 3 (2–5)     | 4 (2–7)     | 3 (2–5.5)    | 3 (2–5)     | 4 (2.5–7)  | 3 (1–5)    | 2.5 (1–4)   | 4 (1–5)     | 3 (2–5.5)   | 3 (1–5)   | 3.5 (1–5) | 948                     |
| Median days primary carer missed work (IQR) | 2.5 (1.5–4) | 2 (1–13)   | 3 (1.5–7.5) | 2 (1.25–2)  | 2 (2–3)     | 3 (1.5–4)  | 1 (1–4)    | 1.5 (1–2.5) | 2 (1–3)     | 3 (1–4)     | 2 (1–2.5) | 2.5 (1.5–3) | 278                     |
| Median days secondary carer missed work (IQR) | 1 (1–1)     | 3 (3–3)     | 1 (1–1)    | 1 (0–2)    | 1 (1–1)    | 1 (0–1)     | 1 (1–1)    | 1.5 (1–2)   | 4 (1–7)     | 2 (1–2)     | 1 (1–1)   | 2 (2–2)   | 37                      |

*Only applies to parents/guardians who were in paid employment
Abbreviations ED Emergency Department, GP general practitioner, IQR interquartile range, N/A not applicable
### Table 2: Exacerbation-related resource use, total and by season

| Resource Type                                                                 | All, n = 264 | Spring, n = 59 | Summer, n = 54 | Autumn, n = 62 | Winter, n = 82 |
|------------------------------------------------------------------------------|--------------|----------------|----------------|----------------|----------------|
| General practitioner visit                                                  | 123 (46.6%)  | 30 (50.9%)     | 26 (48.2%)     | 28 (45.2%)     | 35 (42.7%)     |
| Had a prescription at home to fill/had antibiotics at home                  | 77 (29.2%)   | 15 (25.4%)     | 16 (29.6%)     | 16 (25.8%)     | 28 (34.2%)     |
| Specialist visit                                                             | 69 (26.1%)   | 20 (33.9%)     | 12 (22.2%)     | 15 (24.2%)     | 22 (26.8%)     |
| Physiotherapy                                                                | 41 (15.5%)   | 7 (11.9%)      | 9 (16.7%)      | 10 (16.1%)     | 13 (15.9%)     |
| Telephone advice from respiratory clinic nurse                               | 32 (12.1%)   | 4 (6.8%)       | 3 (5.6%)       | 12 (19.4%)     | 12 (14.6%)     |
| Pathology                                                                    |              |                |                |                |                |
| Haematology (full blood count)                                               | 15 (5.7%)    | 4 (6.8%)       | 4 (7.4%)       | 5 (8.1%)       | 2 (2.4%)       |
| Biochemistry                                                                  | 10 (3.8%)    | 4 (6.8%)       | 3 (5.6%)       | 3 (4.8%)       | 0 (0.0%)       |
| Sputum culture                                                                | 9 (3.4%)     | 1 (1.7%)       | 3 (5.6%)       | 4 (6.5%)       | 1 (1.2%)       |
| Antibiotic blood levels                                                      | 4 (1.5%)     | 0 (0.0%)       | 3 (5.6%)       | 1 (1.6%)       | 0 (0.0%)       |
| Throat swab for virus nucleic acid amplification testing                     | 3 (1.1%)     | 0 (0.0%)       | 1 (1.9%)       | 2 (3.2%)       | 0 (0.0%)       |
| Nasopharyngeal aspirate for virus nucleic acid amplification testing         | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Bronchoalveolar lavage                                                       | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Immunology (radioallergoabsorbent test)                                      | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 1 (1.6%)       | 0 (0.0%)       |
| Missing                                                                      | 4 (1.5%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 4 (4.9%)       |
| In-patient hospital admission                                                | 30 (11.4%)   | 4 (6.8%)       | 9 (16.7%)      | 9 (14.5%)      | 8 (9.8%)       |
| Had ‘hospital in the home’ following inpatient admission                     | 10 (3.8%)    | 0 (0.0%)       | 4 (7.4%)       | 3 (4.8%)       | 2 (2.4%)       |
| Emergency department presentation                                            | 25 (9.5%)    | 3 (5.1%)       | 5 (9.3%)       | 6 (9.7%)       | 9 (11.0%)      |
| Medical imaging                                                              | 21 (8.0%)    | 2 (3.4%)       | 5 (9.3%)       | 5 (8.1%)       | 9 (11.0%)      |
| Chest radiograph                                                            | 14 (5.4%)    | 1 (1.7%)       | 4 (7.4%)       | 3 (4.8%)       | 6 (7.3%)       |
| Chest computed tomography scan                                               | 2 (0.8%)     | 0 (0.0%)       | 1 (1.9%)       | 0 (0.0%)       | 1 (1.2%)       |
| Other                                                                        | 7 (2.7%)     | 1 (1.7%)       | 1 (1.9%)       | 2 (3.2%)       | 3 (3.7%)       |
| Missing                                                                      | 2 (0.8%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Respiratory function testing (spirometry)                                    | 16 (6.1%)    | 4 (6.8%)       | 3 (5.6%)       | 4 (6.5%)       | 5 (6.1%)       |
| Saw other services (during hospitalisation)                                  | 12 (4.6%)    | 3 (5.1%)       | 1 (1.9%)       | 3 (4.8%)       | 5 (6.1%)       |
| Social worker                                                                | 4 (1.5%)     | 1 (1.7%)       | 1 (1.9%)       | 2 (3.2%)       | 0 (0.0%)       |
| Dietician                                                                    | 3 (1.1%)     | 1 (1.7%)       | 0 (0.0%)       | 1 (1.6%)       | 1 (1.2%)       |
| Occupational therapist                                                      | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Cardiologist                                                                 | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Surgical                                                                     | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       |
| Consult liaison                                                              | 1 (0.4%)     | 1 (1.7%)       | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       |
| Dentist                                                                      | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Missing                                                                      | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 1 (1.2%)       |
| Over the counter treatments                                                  | 8 (2.9%)     | 1 (1.7%)       | 2 (3.7%)       | 4 (6.5%)       | 1 (1.2%)       |
| Consultation with community health nurse / respiratory clinic nurse          | 7 (2.7%)     | 1 (1.7%)       | 1 (1.9%)       | 3 (3.2%)       | 3 (3.7%)       |
| Hospital school (during hospitalisation)                                     | 7 (2.7%)     | 2 (3.4%)       | 0 (0.0%)       | 3 (4.8%)       | 2 (2.4%)       |
| Other procedures                                                             | 2 (0.8%)     | 0 (0.0%)       | 1 (1.9%)       | 0 (0.0%)       | 1 (1.2%)       |
| Bronchoscopy                                                                 | 1 (0.4%)     | 0 (0.0%)       | 1 (1.9%)       | 0 (0.0%)       | 0 (0.0%)       |
| Scheduled intravenous line                                                   | 1 (0.4%)     | 0 (0.0%)       | 0 (0.0%)       | 0 (0.0%)       | 3 (3.7%)       |
exacerbations resulted in hospitalization, which is similar to the findings of this study [15]. In the general Australian child population GP attendance was 3.8 visits/year per child between 2012 and 2015 [16], with acute respiratory illness (ARI) the most common reason for presentation. In a cohort of urban Indigenous children aged <5-years, health service utilisation for ARI was 3.6 visits per child-year [17] with an annual mean cost in 2017 Australian dollars of $991 (95% confidence interval 514–1468) per child [18]. Thus children with bronchiectasis are seeking health care as frequently as young children with common ARIIs and, given the predominance of specialist reviews and hospitalizations, the annual cost of bronchiectasis in children is likely to be substantially higher.

Antibiotic use is high in this cohort, although some may be associated with long-term maintenance courses, such as with azithromycin, rather than additional prescriptions for new exacerbations each month. Nevertheless, the prescription rate of 46.0 per 100 child-months (or 552 per 100 child-years) in this cohort is much higher than the antibiotic prescription rate of 41.4 per 100 child-years that was reported for all Australian children aged 0–12 years in 2013 [19]. Of all Australian children dispensed antibiotics for systemic use in 2013, 53% received one systemic antibiotic course, 22% received two, 11% had three and the remainder received four or more. In New Zealand, during 2010–2014, the mean number of antibiotic courses dispensed to children aged <6-years approximated 190 per 100 child-years, with dispensing rates 29–35% higher among Maori/Pacific Islanders compared to New Zealand European children [20]. The higher frequency of antibiotic use among exacerbations during winter that was identified in this study is consistent with overall trends of antibiotics prescribing to Australian children in primary care settings [21].

In any given month, one-quarter of the children in the cohort missed school or childcare due to their bronchiectasis. In a recent study of Alaskan Native children aged 7–17 years with bronchiectasis, 15/34 missed school in the previous 12-months because of respiratory illnesses [22]. A systematic review of social and economic consequences of childhood asthma [23] reported children with asthma were absent from school for 2.1–14.8 days per year. This compares with an average 12-days per child-year in our study. Chronic school absenteeism is associated with suboptimal school achievement [24], which can lead to long-term social and economic disadvantage. Children with chronic illness often demonstrate worse school outcomes than their peers without chronic illness [25]. Furthermore, parents/carers frequently take time from work to care for their child, resulting in lost productivity and income.

The overall high QoL and low cough scores we observed are not surprising given that they were obtained during routine clinical visits, as found in another Brisbane study reporting similar QoL scores for children in a stable state [7]. Our finding that both PC-QoL and CC-QoL scores were negatively associated with cough severity is consistent with PC-QoL significantly declining during exacerbations [7].

This study has several limitations. As all symptom and resource use data were parent-reported and data were collected on a monthly basis, there is a potential for parent/guardian misclassification and recall bias respectively. Future studies could reduce the risk of recall bias, and improve the accuracy of findings, by using medical records to confirm parent-reported data and/or having more frequent follow-up. With respect to the representativeness of the study sample; the differences in baseline characteristics between those participants who completed all monthly follow-ups, and those that did not, suggest that younger children and children with poor birth outcomes were over-represented among the data obtained. Redding et al. [15] reported that among Indigenous children with bronchiectasis, younger children (aged <3-years) were more likely to be hospitalized than older children. Poor birth outcomes are recognized risk factors for respiratory disease [26] and it is plausible that

Table 2 Exacerbation-related resource use, total and by season a (Continued)

| Resource Use | All, n = 264 | Spring, n = 59 | Summer, n = 54 | Autumn, n = 62 | Winter, n = 82 |
|--------------|-------------|---------------|---------------|---------------|---------------|
| n (%)        | n (%)       | n (%)         | n (%)         | n (%)         | n (%)         |
| Maintenance  |             |               |               |               |               |
| Telephone advice from doctor/specialist | 2 (0.8) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 1 (1.2) |
| Alternative therapies | 2 (0.8) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 1 (1.2) |
| Glutathione nebulised medication | 1 | 1 | 0 | 0 | 0 |
| Acupuncture | 1 | 0 | 0 | 0 | 1 |
| Chinese medicine | 1 | 0 | 0 | 0 | 1 |
| Telephone advice from general nurse | 1 (0.4) | 0 (0.0) | 0 (0.0) | 1 (1.6) | 0 (0.0) |

aThere were 7 exacerbations with unknown start dates, and therefore onset season could not be determined.
| Table 3 Resource use at quarterly clinic visits |
|-----------------------------------------------|
|                                                |
| Visit details                                  |
| Consultant Respiratory Physician               | 58 | 31 | 40 | 30 | 33 | 192 (81.4) |
| Respiratory Fellow (advanced trainee)          | 17 | 7  | 5  | 3  | 1  | 33 (14.0)  |
| Nurse                                          | 2  | 2  | 3  | 3  | 1  | 11 (4.7)   |
| Additional clinical services utilised          |
| Respiratory Function testing                   | 51 | 25 | 26 | 26 | 26 | 154 (65.3) |
| Physiotherapy                                  | 27 | 17 | 16 | 14 | 11 | 85 (36.0)  |
| Other allied health                            | 7  | 5  | 4  | 3  | 0  | 19 (8.1)   |
| Respiratory nurse consultant                   | 22 | 14 | 12 | 7  | 7  | 62 (26.3)  |
| Pharmacy - Prescription filled                 | 23 | 14 | 12 | 11 | 7  | 68 (28.4)  |
| Pathology                                      | 11 | 7  | 8  | 4  | 5  | 35 (14.8)  |
| Medical Imaging                                | 3  | 2  | 1  | 3  | 2  | 11 (4.7)   |
| Box study or exercise challenge                | 0  | 1  | 0  | 2  | 1  | 4 (1.7)    |
| Other consults                                 | 3  | 7  | 3  | 3  | 2  | 18 (7.6)   |
| Healthcare card*                               |
| Yes                                           | 60 | 30 | 37 | 25 | 29 | 181 (76.7) |
| No                                            | 15 | 9  | 10 | 9  | 6  | 49 (20.8)  |
| Missing                                       | 2  | 1  | 1  | 2  | 0  | 6 (2.5)    |
| Private health insurance                       |
| Yes                                           | 23 | 13 | 15 | 15 | 9  | 75 (31.8)  |
| No                                            | 50 | 26 | 31 | 18 | 26 | 151 (64.0) |
| Missing                                       | 4  | 1  | 2  | 3  | 0  | 10 (4.2)   |
| Primary carer required to take leave to attend clinic appointment |
| Sick/care’s leave taken                        | 10 | 2  | 5  | 6  | 3  | 26 (11.0)  |
| No leave required                             | 27 | 14 | 21 | 11 | 15 | 88 (37.3)  |
| Unpaid leave taken                            | 7  | 0  | 2  | 4  | 2  | 15 (6.4)   |
| Not in paid employment                        | 25 | 11 | 12 | 5  | 8  | 61 (25.9)  |
| Did not attend                                | 3  | 0  | 1  | 3  | 2  | 9 (3.8)    |
| Other                                         | 4  | 4  | 3  | 3  | 3  | 17 (7.2)   |
| Missing                                       | 1  | 9  | 4  | 4  | 2  | 20 (8.5)   |
| Secondary carer required to take leave to attend clinic appointment |
| Sick/care’s leave taken                        | 3  | 1  | 2  | 2  | 2  | 10 (4.2)   |
| No leave required                             | 7  | 2  | 1  | 3  | 2  | 15 (6.4)   |
| Unpaid leave taken                            | 1  | 1  | 0  | 0  | 0  | 2 (0.9)    |
| Not in paid employment                        | 1  | 1  | 0  | 2  | 0  | 4 (1.7)    |
| Did not attend                                | 41 | 15 | 16 | 13 | 16 | 101 (42.8) |
| Other                                         | 1  | 1  | 0  | 1  | 0  | 3 (1.3)    |
| Missing/NA                                    | 23 | 19 | 29 | 15 | 15 | 101 (42.8) |
| Additional carer required to take leave to attend clinic appointment |
| No leave required                             | 1  | 0  | 0  | 0  | 0  | 1 (0.4)    |
| Not in paid employment                        | 1  | 0  | 0  | 0  | 0  | 1 (0.4)    |
| Did not attend                                | 5  | 2  | 3  | 0  | 0  | 10 (4.2)   |
| Missing/NA                                    | 70 | 38 | 45 | 36 | 35 | 224 (94.9) |

*A healthcare card is a government-issued card, which provides the cardholder with access to additional subsidies for medicines and/or healthcare services within the public healthcare system. Healthcare cards are issued to individuals who meet certain social and/or economic criteria.
poor birth outcomes may be associated with higher resource use as a result of earlier and more severe respiratory disease. The study was conducted in three centers where quarterly clinical reviews are standard care and where the relationship between clinicians and their patients is such that families have ongoing access to advice and support when needed. Hence our findings may apply only to centers with similar practices. Furthermore, whilst the clinical characteristics of our children are similar to other bronchiectasis studies conducted in the same study centres [9], the study findings may not be generalizable to children with bronchiectasis elsewhere [27, 28] given reported differences in clinical presentations and underlying etiology. Nevertheless, as shown in Table 3, the attendance at scheduled visits following enrolment was only about 50% for reasons that are uncertain. It may reflect visits that were scheduled when the child was well and the parent/carer did not consider attendance necessary and/or the competing demands of families with respect to work and school, a concern reported by New Zealand mothers of children with bronchiectasis [29]. The small number of parents/carers and children who completed QoL and cough severity questionnaires is likely to have biased our findings, particularly as most questionnaires were completed at clinic visits. It is plausible that the QoL of parents/carers and children who regularly attend scheduled visits and receive ongoing specialist care may be better than those who do not [30]. Alternatively, those not attending may have milder disease. Finally, the tool used to measure cough severity has been reported to have some limitations with respect to its correlation with cough frequency. However there are few other validated tools for assessing cough severity in children [31] and this tool has been used repeatedly in other paediatric respiratory studies, enabling comparisons to be made between studies [32–34].

Conclusions

To our knowledge, this study is the first to provide disease burden estimates by measuring healthcare resource use for managing pediatric bronchiectasis. It suggests resource use is substantial. Further research is needed to more precisely estimate the cost of disease to families, the healthcare sector and third parties in a broader population of children with bronchiectasis. Such data are critical for informing policy and designing and evaluating interventions to reduce the burden of disease.

Additional file

Additional file 1: Table S1. Parent and child-reported cough severity scores at time of clinic visits. Table S2. Correlations between parent and child-reported quality-of-life (QoL) and parent and child-reported cough severity at baseline and months 3, 6, 9 and 12. Table S3. Comparison of baseline characteristics between those participants who completed all 12-monthly follow-up tasks and those participants who did not. (DOCX 21 kb)

Abbreviations

ARI: Acute respiratory illness; CC-QoL: Chronic cough quality of life; ED: Emergency department; GP: General practitioner; HR-QoL: Health-related quality of life; IQR: Interquartile range; NHMRC: National Health & Medical Research Council; NZD: New Zealand Dollar; PC-QoL: Parent-cough-specific quality of life; QoL: Quality of life; SD: Standard deviation

Acknowledgements

We thank the children and their families for participating in the study. We also thank the research nurses/staff Helen Petsky, Joanne Tuppen, Michelle Lewis and Sandra Goodwin (Centre for Children’s Health Research), Charmaine Mobberley (Auckland) and Gabrielle McCallum, Lesley Versteegh (Menzies, Darwin) for their help with data collection.

Authors’ contributions

YLT analyzed the data and prepared the first and final versions of the manuscript. AC, KG and VG conceived the study, prepared the study protocol and data collection instruments and oversaw study implementation. JM, CB, IBM, HB and GB provided significant input into study implementation. KO assisted with the analysis and interpretation of study results and the preparation of the manuscript. All authors reviewed and approved the final manuscript.

Funding

This work was supported by the Australian National Health and Medical Research Council (NHMRC; project grant number 1019834) the NHMRC Centre for Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children (1040830), Cure Kids, Auckland, New Zealand (3702764/3539) and Financial Markets Foundation for Children. VG was supported by an NHMRC post-graduate scholarship (1075119). ABC is supported by an NHMRC practitioner fellowship (1058213). KFO was supported by a NHMRC CRE fellowship (10450830). The funding sources had no role in the design and conduct of the study and the authors were independent of the funding agencies and all authors had full access to the data.
Available data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Written informed consent was obtained from a parent/guardian before enrolment; assent was obtained from children aged > 12-years. Human Research Ethics Committees at all participating sites approved the study: Children’s Health Queensland Human Research Ethics Committee, Australia (HREC/12/QRCH/159); Human Research Ethics Committee of the Northern Territory Department of Health and Menzies School of Health Research, Australia (HOMER 2012–1705); Northern Australia Human and Disability Ethics Committee, New Zealand (HDEC 13/N7TA/238/AMO4).

Consent for publication
Written informed consent specified consent for publication.

Competing interests
The authors declare that they have no competing interests.

Author details
1Institute of Health & Biomedical Innovation @ Centre for Children’s Health Research, Queensland University of Technology, 62 Graham Street, South Brisbane, Queensland 4101, Australia. 2School of Medicine and Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland 4222, Australia. 3Departments of Infectious Diseases and Paediatrics, Gold Coast Health, Gold Coast, Queensland 4215, Australia. 4Department of Paediatrics, University of Auckland, Auckland, New Zealand. 5Respiratory Department, Starship Children’s Hospital, Auckland, New Zealand. 6Department of Respiratory Medicine, Queensland Children’s Hospital, South Brisbane, Queensland 4101, Australia. 7School of Medicine, The University of Queensland, Herston, Queensland 4006, Australia. 8Child Health Division, Menzies School of Health Research, Tiwi, Northern Territory 0810, Australia.

Received: 12 March 2019 Accepted: 9 August 2019
Published online: 13 August 2019

References
1. Goyal V, Grimwood K, Marchant J, Masters IB, Chang AB. Pediatric bronchiectasis: no longer an orphan disease. Pediatr Pulumol. 2016;51(5):450–69.
2. McCallum GB, Binks MJ. The epidemiology of chronic suppurative lung disease and bronchiectasis in children and adolescents. Front Pediatr. 2017;5:27.
3. Chandrasekanan R, Mac Aogáin M, Chalmers JD, Elborn SJ, Chotimall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018;18(18):83.
4. Nathan AM, de Bruyne JA, Eg KP, Thavagnanam S. Quality of life in children with non-cystic fibrosis bronchiectasis. Front Pediatr. 2017;5:84.
5. Schmets G, Rajan D, Kadandale S. Strategizing national health in the 21st century: a handbook. Geneva: WHO; 2016.
6. Aliberti S, Masefield S, Polverino E, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC clinical research collaboration. Eur Respir J. 2016;48(3):632–47.
7. Kapur N, Masters IB, Newcombe P, Chang AB. The burden of disease in pediatric non-cystic fibrosis bronchiectasis. Chest. 2012;141(4):1018–24 7.
8. Blyib S, Milne R, Beasley R. Hospital admissions for non-cystic fibrosis bronchiectasis in New Zealand. BMC Pulm Med. 2018;18(1):72.
9. Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2018;390(10154):1197–206.
10. Kapur N, Masters IB, Morris PS, Galligan J, Ware R, Chang AB. Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis. Pediatr Pulumol. 2012;47(1):68–75.
11. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for indigenous children with non-cystic fibrosis bronchiectasis: a chronic suppurative lung disease (bronchiectasis intervention study) a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(8):610–20.
12. Newcombe PA, Sheffield JK, Petsky HL, Marchant JM, Willis C, Chang AB. Validation of a parent-proxy of quality of life questionnaire for paediatric chronic cough (PC-QOL). Thorax. 2010;65(9):819–23.
13. Newcombe PA, Sheffield JK, Petsky HL, Marchant JM, Willis C, Chang AB. A child chronic cough-specific quality of life measure development and validation. Thorax. 2016;71(8):695–700.
14. Chang A, Newman R, Carlin J, Phelan P, Robertson C. Subjective scoring of cough in children: parent-completed vs child-completed diary cards vs an objective method. Eur Respir J. 1998;11(2):462–6.
15. Redding GJ, Singleton RJ, Valery PC, et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. Chest. 2014;146(3):762–74.
16. Bayram C, Harrison C, Charles J, Britt H. The kids are alright–Changes in GP consultations with children 2000–15. Aust Fam Physician. 2015;44(12):877.
17. Hall KC, Chang AB, Anderson J, Arnold D, Otim M, O’Grady KE. Health service utilisation amongst urban aboriginal and Torres Strait islander children aged younger than 5 years registered with a primary health-care service in south-East Queensland. J Paediatr Child Health. 2018;54(6):671–6.
18. Lovie-Toon YG, McPhail SM, Au-Yeung YT, et al. The cost of acute respiratory infections with cough among urban Aborginal and Torres Strait islander children. Front Pediatr. 2018;6:579.
19. Gaddhbanova S, Roughhead E. Prescribed antibiotic use in Australian children aged 0-12 years. Aust Fam Physician. 2016;45(3):134.
20. Hobbs MR, Grant CC, Ritchie SR, et al. Antibiotic consumption by New Zealand children: exposure is near universal by the age of 5 years. J Antimicrob Chemother. 2017;72(6):1832–40.
21. Yan J, Havens L, Turner L, Mazza D, Pearce C, Buttery J. Antimicrobial prescribing for children in primary care. J Paediatr Child Health. 2019;55(5):154–8.
22. Kinghorn B, Singleton R, McCallum GB, et al. Clinical course of chronic suppurative lung disease and bronchiectasis in Alaska native children. Pediatr Pulumol. 2018;53(12):1662–9.
23. Milton B, Whitehead M, Holland P, Hamilton V. The social and economic consequences of childhood asthma across the lifespan: a systematic review. Child Care Health Dev. 2004;30(6):711–28.
24. Black LL, Zablotsky B. Chronic School Absenteeism among Children with Selected Developmental Disabilities: National Health Interview Survey, 2014–2016. National Health Statistics Reports; no 118. Hyattsville: National Center for Health Statistics; 2018.
25. Lunn A, Wakefield C, Donnan B, Burns M, Fardell J, Marshall G. Understanding the school experiences of children and adolescents with serious chronic illness: a systematic meta-review. Child Care Health Dev. 2017;43(5):645–62.
26. Parisgott J, Dunstan F, Watkins WJ, et al. Gestational age, birth weight, and risk of respiratory hospital admission in childhood. Pediatrics. 2013;132(6):e1562–9.
27. Satter O, Yesil AM, Emiraloglu N, et al. A review of the etiology and clinical presentation of non-cystic fibrosis bronchiectasis: a tertiary care experience. Respir Med. 2018;137:35–9.
28. Brower KS, Del Vecchio MT, Aronoff SC. The etiologies of non-CF bronchiectasis in childhood: a systematic review of 989 subjects. BMC Pediatr. 2014;14(1):299.
29. Jepsen N, Charania NA, Mooney S. Health care experiences of mothers of children with bronchiectasis in Counties Manukau, Auckland, New Zealand. BMC Serv Res. 2018;18(1):722.
30. Chang AB, Bush A, Grimwood K. Bronchiectasis in children: diagnosis and treatment. Lancet. 2018;392(10150):866–79.
31. Schmit KM, Coeytaux RR, Goode AP, et al. Evaluating cough assessment tools: a systematic review. Chest. 2013;144(6):1819–26.
32. O’Grady K-AF, Drescher BJ, Goyal V, et al. Chronic cough postacute respiratory illnesses in children: a cohort study. Arch Dis Child. 2017;102(11):1044–8.
33. Marchant J, Masters IB, Champion A, Petsky H, Chang AB. Randomised controlled trial of amoxicillin clavulanate in children with chronic wet cough. Thorax. 2012;67(3):689–93.
34. Petsky HL, Acworth JP, Clark R, Theaie DM, Masters IB, Chang AB. Asthma and protracted bronchitis: who fares better during an acute respiratory infection? J Paediatr Child Health. 2009;45(1–2):42–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.